Intercept Pharmaceuticals (ICPT) Outlook Unchanged Following Earnings - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $346 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) saying the outlook is unchanged following earnings.

Skorney commented, "3Q15 served as more of a housekeeping event than anything else. The company focused on discussing preparation for PBC AdCom and launch early 2016 and providing more granularity on additional clinical trial plans at their upcoming AASLD event (November 16) and the analyst day (December 1)."

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $176.70 yesterday.

You May Also Be Interested In

• Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
• Freedom Broker Upgrades Garrett Motion (GTX) to Buy
• Goldman Sachs Revises China Jewelry Stocks Amid Gold Price Retreat